BR0316152A - Compostos de pirimidina - Google Patents
Compostos de pirimidinaInfo
- Publication number
- BR0316152A BR0316152A BR0316152-8A BR0316152A BR0316152A BR 0316152 A BR0316152 A BR 0316152A BR 0316152 A BR0316152 A BR 0316152A BR 0316152 A BR0316152 A BR 0316152A
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine compounds
- cdks
- cyclin
- proliferative
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTOS DE PIRIMIDINA". A presente invenção refere-se às pirimidinas substituídas da fórmula I, sua preparação, composições farmacêuticas contendo as mesmas e seu uso como inibidores de quinases dependentes de ciclina (CDKs) e conseq³entemente seu uso no tratamento de distúrbios proliferativos e/ou viróticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0226583.3A GB0226583D0 (en) | 2002-11-14 | 2002-11-14 | Compounds |
PCT/GB2003/004973 WO2004043953A1 (en) | 2002-11-14 | 2003-11-14 | Pyrimidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316152A true BR0316152A (pt) | 2005-09-27 |
Family
ID=9947823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316152-8A BR0316152A (pt) | 2002-11-14 | 2003-11-14 | Compostos de pirimidina |
Country Status (17)
Country | Link |
---|---|
US (2) | US7432260B2 (pt) |
EP (2) | EP1567522B1 (pt) |
JP (1) | JP4681880B2 (pt) |
CN (1) | CN100415740C (pt) |
AT (1) | ATE373653T1 (pt) |
AU (1) | AU2003301977A1 (pt) |
BR (1) | BR0316152A (pt) |
CA (1) | CA2502190A1 (pt) |
CY (1) | CY1106933T1 (pt) |
DE (1) | DE60316468T2 (pt) |
DK (1) | DK1567522T3 (pt) |
ES (1) | ES2293094T3 (pt) |
GB (1) | GB0226583D0 (pt) |
MX (1) | MXPA05005199A (pt) |
NZ (1) | NZ539670A (pt) |
PT (1) | PT1567522E (pt) |
WO (1) | WO2004043953A1 (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
RS53109B (en) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
JPWO2005113550A1 (ja) * | 2004-05-20 | 2008-03-27 | 三菱ウェルファーマ株式会社 | アミノピリミジン誘導体及びその医薬としての用途 |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
MX2007002169A (es) * | 2004-08-27 | 2007-08-14 | Cyclacel Ltd | Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes. |
KR20070084067A (ko) | 2004-10-13 | 2007-08-24 | 와이어쓰 | N-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
BRPI0517253A (pt) * | 2004-10-28 | 2008-10-07 | Irm Llc | compostos e composições como moduladores de trajetória de ouriço |
AU2005316312B2 (en) * | 2004-12-17 | 2009-10-22 | Amgen, Inc. | Aminopyrimidine compounds and methods of use |
WO2006076442A2 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
JP2009515984A (ja) | 2005-11-15 | 2009-04-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なアザインダゾール |
US7514566B2 (en) * | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
WO2007132220A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
WO2007132221A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
EP2064322B1 (en) * | 2006-06-14 | 2012-04-25 | Vertex Pharmceuticals Incorporated | Crystal structure of polo-like kinase 3 (plk3) and binding pockets thereof |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
CA2693473A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
EP2203442B1 (en) * | 2007-09-28 | 2012-06-20 | Nerviano Medical Sciences S.r.l. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
EP2265607B1 (en) | 2008-02-15 | 2016-12-14 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
RU2011140238A (ru) | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
HU0900798D0 (en) * | 2009-12-21 | 2010-03-01 | Vichem Chemie Kutato Kft | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity |
JP6525474B2 (ja) | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼ阻害剤と抗cd30抗体の併用 |
CN105267214B (zh) * | 2014-07-21 | 2019-04-30 | 沈阳化工研究院有限公司 | N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用 |
SI3204381T1 (sl) | 2014-10-08 | 2022-10-28 | Redx Pharma Plc | Derivati N-piridinil acetamida kot inhibitorji WNT signalne poti |
PL3204378T6 (pl) | 2014-10-08 | 2022-09-12 | Redx Pharma Plc | Pochodne n-pirydynylo acetamidu jako inhibitory szlaku sygnałowego wnt |
WO2017015316A1 (en) | 2015-07-21 | 2017-01-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
CN108349964B (zh) * | 2015-08-04 | 2021-06-01 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
US10696642B2 (en) | 2015-09-23 | 2020-06-30 | The General Hospital Corporation | TEAD transcription factor autopalmitoylation inhibitors |
US20170283445A1 (en) | 2016-04-05 | 2017-10-05 | University Of South Carolina | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins |
CN109985241A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
US11162083B2 (en) | 2018-06-14 | 2021-11-02 | University Of South Carolina | Peptide based inhibitors of Raf kinase protein dimerization and kinase activity |
US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254879B1 (en) * | 1991-09-27 | 2001-07-03 | Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. | Methods of treating protozoal diseases |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001030778A1 (en) * | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
NZ521068A (en) * | 2000-03-29 | 2005-04-29 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
EP1345922B1 (en) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
EP1430051B1 (en) * | 2001-09-28 | 2006-12-27 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
AU2002336616A1 (en) * | 2001-10-03 | 2003-04-14 | Douglas D. Snyder | Pilot authentication using voice biometric |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
BRPI0412351A (pt) * | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | derivados e piridilamino-pirimidina como inibidores de proteìna quinase |
AU2004261484A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
GB0328180D0 (en) * | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
MX2007002169A (es) * | 2004-08-27 | 2007-08-14 | Cyclacel Ltd | Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes. |
-
2002
- 2002-11-14 GB GBGB0226583.3A patent/GB0226583D0/en not_active Ceased
-
2003
- 2003-11-14 CA CA002502190A patent/CA2502190A1/en not_active Abandoned
- 2003-11-14 MX MXPA05005199A patent/MXPA05005199A/es active IP Right Grant
- 2003-11-14 DE DE60316468T patent/DE60316468T2/de not_active Expired - Lifetime
- 2003-11-14 EP EP03811029A patent/EP1567522B1/en not_active Expired - Lifetime
- 2003-11-14 AU AU2003301977A patent/AU2003301977A1/en not_active Abandoned
- 2003-11-14 NZ NZ539670A patent/NZ539670A/en unknown
- 2003-11-14 AT AT03811029T patent/ATE373653T1/de active
- 2003-11-14 DK DK03811029T patent/DK1567522T3/da active
- 2003-11-14 EP EP07017867A patent/EP1864983A1/en not_active Withdrawn
- 2003-11-14 WO PCT/GB2003/004973 patent/WO2004043953A1/en active IP Right Grant
- 2003-11-14 PT PT03811029T patent/PT1567522E/pt unknown
- 2003-11-14 CN CNB2003801033182A patent/CN100415740C/zh not_active Expired - Fee Related
- 2003-11-14 JP JP2004550846A patent/JP4681880B2/ja not_active Expired - Fee Related
- 2003-11-14 ES ES03811029T patent/ES2293094T3/es not_active Expired - Lifetime
- 2003-11-14 BR BR0316152-8A patent/BR0316152A/pt not_active IP Right Cessation
-
2004
- 2004-11-17 US US10/991,942 patent/US7432260B2/en not_active Expired - Lifetime
-
2007
- 2007-10-15 CY CY20071101326T patent/CY1106933T1/el unknown
-
2008
- 2008-07-29 US US12/220,857 patent/US7897605B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CY1106933T1 (el) | 2012-09-26 |
NZ539670A (en) | 2007-11-30 |
GB0226583D0 (en) | 2002-12-18 |
US7897605B2 (en) | 2011-03-01 |
DE60316468D1 (de) | 2007-10-31 |
US7432260B2 (en) | 2008-10-07 |
ATE373653T1 (de) | 2007-10-15 |
PT1567522E (pt) | 2007-10-09 |
CN1711258A (zh) | 2005-12-21 |
EP1567522A1 (en) | 2005-08-31 |
US20080287439A1 (en) | 2008-11-20 |
DE60316468T2 (de) | 2008-06-26 |
AU2003301977A1 (en) | 2004-06-03 |
EP1864983A1 (en) | 2007-12-12 |
EP1567522B1 (en) | 2007-09-19 |
CA2502190A1 (en) | 2004-05-27 |
ES2293094T3 (es) | 2008-03-16 |
CN100415740C (zh) | 2008-09-03 |
US20050192300A1 (en) | 2005-09-01 |
JP2006514619A (ja) | 2006-05-11 |
DK1567522T3 (da) | 2007-11-05 |
JP4681880B2 (ja) | 2011-05-11 |
MXPA05005199A (es) | 2005-08-18 |
WO2004043953A1 (en) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316152A (pt) | Compostos de pirimidina | |
BRPI0511616A (pt) | compostos | |
MEP13408A (en) | Cdk inhibiting pyrimidines, production thereof and their use as medicaments | |
ME00158B (me) | Pirimidini supstituisani sulfoksiiminima kao cdk-i/ili vegf-inhibitori, njihovo dobijanje i primjena kao lijeka | |
BR0212944A (pt) | N-(4-(4-metiltiazol-5-il)-pirimidin-2-il)-n-fenilaminas como compostos antiproliferativos | |
BRPI0314001B8 (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas | |
BRPI0507644A (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
BRPI0616987A2 (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
ME00275B (me) | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE | |
BRPI0407827A (pt) | compostos de aminoeteroarila como inibidores de proteìna cinase | |
TW200628452A (en) | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | |
WO2004078682A3 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
SV2005002148A (es) | "compuestos moduladores de la actividad c-kit y usos de los mismos" | |
ATE377592T1 (de) | Neurotropische substituierte pyrimidine | |
GB2375534B (en) | Anti-cancer compounds | |
BRPI0512547A (pt) | pirimidinas | |
BR0213185A (pt) | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase | |
DE60101372D1 (de) | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
BRPI0418887A (pt) | nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos | |
MXPA04003297A (es) | Derivados novedosos de benzotiacina su preparacion y uso. | |
BR0208814A (pt) | Uso de derivados de ariletenossulfonamida | |
ECSP034929A (es) | Pirimidinas inhibidoras de cdk, su preparación y uso como medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: CYCLACEL LIMITED (GB) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014. |